Use of Clindamycin in Pediatric Infections

Authors and Disclosures

Marcia L. Buck, Pharm.D., FCCP, Contributing Editor

Kristi N. Hofer, Pharm.D, Michelle W. McCarthy, Pharm.D., Editorial Board

Sidebar: Formulary Update

The following actions were taken by the Pharmacy and Therapeutics Committee at their meeting on 1/24/08:

1. Mycophenolate sodium (Myfortic®) was added to the Outpatient Formulary for patientswith significant adverse gastrointestinal effectsfrom mycophenolate mofetil.

2. Sodium phenylbutyrate (Buphenyl®) wasadded to both the Inpatient and OutpatientFormularies for the treatment of patients withurea cycle disorders.

3. A combination metered dose inhaler withbudesonide, a corticosteroid, and formoterol, along-acting beta2-adrenergic agonist,(Symbicort®) was added to both the Inpatient andOutpatient Formularies. In a class review of theinhaled corticosteroids, triamcinolone(Azmacort®) was removed from the Formularyand mometasone furoate (Asmanex®) was added.

4. In an annual Formulary class review,trimethobenzamide (Tigan®) suppositories wereremoved from the Inpatient and OutpatientFormularies and aluminum hydroxide(Gaviscon®) was removed from the InpatientFormulary.

5. The results of medication utilizationevaluations involving rifaximin, IVpromethazine, and argatroban were presented, aswell as the Non-Formulary Quarterly Report.